Background Though intravenous (IV) ketamine and intranasal (IN) esketamine are noted to
be efficacious for treatment-resistant depression (TRD), access to each of these treatments …

Abstract Introduction Intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS)
are effective in the acute treatment of Treatment-Resistant Depression (TRD). Studies …

Abstract Treatment-resistant depression (TRD) represents a severe clinical condition with
high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been …

Introduction and aims Treatment-resistant depression (TRD) occurs when at least two
different antidepressants, taken at the right dosage, for adequate period of time and with …

The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant
depression (TRD) has been confirmed by real-world studies. Available evidence derived …

Background. The efficacy and safety of esketamine nasal spray (ESK) were established in
registration trials in patients with treatment‐resistant depression (TRD). This French real …

Introduction Dopaminergic transmission impairment has been identified as one of the main
neurobiological correlates of both depression and clinical symptoms commonly associated …

Objective: The study aimed to conduct a multidimensional evaluation of potential adverse
events (AEs) of escitalopram oxalate based on the FDA adverse event reporting system …

Background Ketamine was developed as an anesthetic. Esketamine is the isolated S-
enantiomer of racemic ketamine. They provide new avenues for the treatment of depression …

Spravato and other drugs with consciousness-altering effects show significant promise for
treating various mental health disorders. However, the effects of these treatments …